Lenvatinib causes reduced expression of carnitine/organic cation transporter 2 and carnitine deficiency in the skeletal muscle of rats

• Published in: Toxicology letters Vol. 366; pp. 17 - 25
• Main Authors: Jing, Zheng, Okubo, Hironao, Morishige, Jun-ichi, Xu, Pingping, Hasan, Nazmul, Nagata, Naoto, Ando, Hitoshi
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.08.2022
• Subjects: Carnitine; Carnitine/organic cation transporter 2; Lenvatinib; Mitochondria; Skeletal muscle; Carnitine/organic cation transporter 2; CPT; HCC; OCTN; FGFR; Skeletal muscle; Carnitine; CACT; KIM-1; Mitochondria; TKI; mTOR; VEGFR; Lenvatinib

Lenvatinib, an oral tyrosine kinase inhibitor, is widely used to treat several types of advanced cancers but often causes muscular adverse reactions. Although carnitine supplementation may prevent these effects, the mechanism underlying lenvatinib-induced skeletal muscle impairment remains poorly un...